Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Predictive serum biomarkers for response to Interferon-ß(IFN-ß) in relapsing Multiple Sclerosis (MS)

FY 2010-11

Summary
At present there is no rational way to instruct an individual with relapsing remitting multiple sclerosis (RRMS) , whether or not to use IFN-beta or to try the other first line drug for RRMS, glatiramer. These proposed studies aim at following up on the April 2010 publication in Nature Medicine from the Steinman lab. They could lead to a potential diagnostic test to predict who will benefit from IFN-beta. This would mark the first time that a predictive test would be available for deciding on a therapeutic to MS. If we want to practice economically efficient medicine, such a predictive test would be an important breakthrough. Moreover, it would enable us to start the most efficacious therapy as soon as possible.
Program
CIHR Fellowship
Location
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
226273
Name
Ajami Bahareh
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Predictive serum biomarkers for response to Interferon-ß(IFN-ß) in relapsing Multiple Sclerosis (MS)
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Immunology; Multiple Sclerosis
Abstract
At present there is no rational way to instruct an individual with relapsing remitting multiple sclerosis (RRMS) , whether or not to use IFN-beta or to try the other first line drug for RRMS, glatiramer. These proposed studies aim at following up on the April 2010 publication in Nature Medicine from the Steinman lab. They could lead to a potential diagnostic test to predict who will benefit from IFN-beta. This would mark the first time that a predictive test would be available for deciding on a therapeutic to MS. If we want to practice economically efficient medicine, such a predictive test would be an important breakthrough. Moreover, it would enable us to start the most efficacious therapy as soon as possible.
Competitiondate
201102
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Ajami, Bahareh
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
Direct Payment - $150,000 Grant (2010-11) | Canada Spends